Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference

Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will be presenting a corporate overview at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 taking place in Miami, FL at the Loews Miami Beach Hotel on Monday, June 8, 2026 at 8:00am ET.

A live webcast of the event will be available through this link. A replay of the event will also be available on Praxis' "Events and Presentations" website after each event for approximately 180 days.

About Praxis  
Praxis Precision Medicines is a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and X/Twitter.


Investor Contact:  Praxis Precision Medicines  investors@praxismedicines.com  857-702-9452    Media Contact: Dan Ferry LifeSci Advisors Daniel@lifesciadvisors.com 617-430-7576

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

PRAX
The Conversation (0)
Praxis Precision Medicines to Participate in Upcoming Investor Conferences

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

Praxis Precision Medicines Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be... Keep Reading...
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results

Plans to initiate two efficacy studies investigating PRAX-628 in focal onset seizures in the second half of 2024 and first half of 2025, respectively Continued strong recruitment for the pivotal Essential3 trials in Essential Tremor (ET), with over 50,000 pre-screening forms and over 7,000... Keep Reading...
Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024

Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024

Praxis Precision Medicines Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will report... Keep Reading...
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635

Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on May 1, 2024,... Keep Reading...

Interactive Chart

Latest Press Releases

Related News